Immunogenicity, Efficacy, and Correlates of Protection
This area covers how vaccines induce an immune response (immunogenicity), how that response is measured, and how it is linked to clinical protection. It connects three ideas that are often conflated: the immune response a vaccine elicits, the protection demonstrated in controlled trials (efficacy) and in routine use (effectiveness), and the measurable immune markers that predict protection (correlates of protection).
Definition
Immunogenicity is the capacity of a vaccine to elicit a measurable immune response; efficacy and effectiveness describe the protection it confers under trial and real-world conditions, respectively; and a correlate of protection is an immune marker that is statistically and ideally mechanistically associated with that protection.
Scope
The entry orients the reader to the conceptual chain running from antigen exposure to measurable immunity to demonstrated protection. It introduces immunogenicity endpoints (antibody titres, neutralization, cellular responses), the efficacy-versus-effectiveness distinction, and the logic by which an immune measurement is validated as a correlate of protection. It treats these as reference concepts in vaccinology and immunology, not as clinical guidance.
Sub-topics
Core questions
- What immune response does a vaccine induce, and how is it quantified?
- How does protection demonstrated in a randomized trial (efficacy) differ from protection observed in routine use (effectiveness)?
- Which immune measurements predict protection, and when can a marker be used as a surrogate endpoint?
Key concepts
- Immunogenicity
- Vaccine efficacy versus effectiveness
- Correlate of protection (mechanistic vs non-mechanistic)
- Neutralizing antibody titre
- Cell-mediated immunity
- Surrogate endpoint
- Seroconversion and seroprotection thresholds
Key theories
- Correlate of protection framework
- Plotkin's framework distinguishes a mechanistic correlate of protection (an immune response causally responsible for protection) from a non-mechanistic correlate (a marker that predicts protection without being the direct cause), and sets out the evidence needed before an immune measure can substitute for a clinical endpoint.
Mechanisms
A vaccine presents antigen to the immune system, which mounts humoral (antibody-producing) and cellular (T-cell) responses and establishes immunological memory. Immunogenicity studies measure these responses as antibody titres, neutralizing activity, and antigen-specific T-cell frequencies. Efficacy trials then test whether vaccinated people experience fewer outcomes than unvaccinated controls, and modelling work links the size of the immune response to the degree of protection; for SARS-CoV-2 vaccines, for example, neutralizing antibody level was shown to be highly predictive of protection from symptomatic infection.
Clinical relevance
Understanding immunogenicity and correlates of protection underpins how vaccines are evaluated, licensed, and monitored, and how the durability of protection is interpreted. The concepts describe how vaccine evidence is generated and appraised; they are reference material for the health sciences and are not a basis for individual vaccination decisions, which belong to clinicians and public-health authorities.
Epidemiology
Vaccine performance is characterized first in controlled efficacy trials and then in observational effectiveness studies in the general population, where confounding and bias must be addressed. Correlates of protection, once established, can accelerate the evaluation of new or updated vaccines by allowing immunogenicity to stand in for large clinical-endpoint trials.
Evidence & guidelines
The conceptual foundations are set out in Plotkin's correlates-of-protection papers and in general vaccinology reviews; the methodological cautions for observational effectiveness studies are discussed by Lipsitch and colleagues. These are reference syntheses rather than prescriptive clinical guidelines.
History
The idea that a measurable immune response can predict protection dates to early serological work on antitoxins and on antibody thresholds for diseases such as diphtheria and tetanus. Plotkin's reviews in the 2000s and 2010s consolidated the modern vocabulary of correlates of protection, and the COVID-19 pandemic prompted intensive new work quantifying the relationship between neutralizing antibody levels and protection.
Debates
- When can an immune marker replace a clinical endpoint?
- Establishing a marker as a valid surrogate requires evidence that it predicts protection across settings; mechanistic and non-mechanistic correlates carry different inferential weight, and over-reliance on a single marker (such as antibody titre) can miss the contribution of cellular immunity.
- How reliable are real-world effectiveness estimates?
- Observational effectiveness studies are vulnerable to confounding, selection, and bias, so causal interpretation of effectiveness and waning requires careful design and analysis.
Key figures
- Stanley A. Plotkin
- Andrew J. Pollard
- Peter B. Gilbert
- Marc Lipsitch
- Miles P. Davenport
Related topics
Seminal works
- plotkin-2010
- plotkin-gilbert-2012
- pollard-bijker-2021
- khoury-2021
Frequently asked questions
- What is the difference between vaccine efficacy and effectiveness?
- Efficacy is the protection measured under the controlled conditions of a randomized trial, while effectiveness is the protection observed when the vaccine is used in routine practice in the broader population, where conditions and populations are more varied.
- What is a correlate of protection?
- It is an immune measurement, such as an antibody titre, that is associated with protection from disease; a mechanistic correlate is causally responsible for protection, whereas a non-mechanistic correlate predicts protection without being its direct cause.